HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Education
Visit Zacks'
Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


RDY: Dr Reddys Labs Ltd - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

DR REDDYS LABS LTD (NYSE)
RDY 23.66 0.32 (1.37%) Vol.  511,705 16:01 ET

Day Low - High 23.13 - 23.73
52wk Low - High 7.27 - 27.33
Avg Volume 543,916
Industry MED-GENERIC DRG
Market Cap 3.94 B
Div - Yield 0.11 - 0.47
PE (forward) 19.29
PEG Ratio .92
Current Year Est. 1.21
EPS Last Year 1.37
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 01/19/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 01/26/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
DR REDDYS LABS LTD RDY PREMIUM
IMPAX LABORATRS IPXL PREMIUM
MYLAN INC MYL PREMIUM
TEVA PHARM ADR TEVA PREMIUM
See all MED-GENERIC DRG Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.17
ABR (Last Week) 2.17
# of Recs in ABR 6
Average Target Price 26.69
Industry Rank by ABR 136 out of 217
Rank in Industry 7 out of 11
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate RDY?
Buy
Sell
Find out what the Zacks Community
thinks of RDY at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR RDY
Zacks Equity Research: Report for RDY
Jan 26, 2010
Zacks Blog: Dr Reddy Reports, Slashes Guidance
Jan 21, 2010
Zacks Blog: Zacks #1 Rank Additions for Tuesday
Jan 19, 2010
Zacks Blog: Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Inc., Teva, Mylan, Dr. Reddy’s and Par Pharma
Jan 15, 2010
Zacks Blog: Watson Set to Top Expectations
Jan 14, 2010
Zacks Blog: Glaxo Exercises Drug Option
Jan 12, 2010
Zacks Blog: Neutral on Watson
Jan 08, 2010
Zacks Blog: Pfizer Strides into Generics Pact
Jan 08, 2010
More Zacks Commentary
NEWS
Drug formulations pep up sector, but contract research spoils Q3 party
Feb 03, 2010
Aegis Therapeutics and Dr. Reddy's Announce Strategic Alliance
Jan 25, 2010
Dr. Reddy's Q3 FY10 Financial Results
Jan 20, 2010
Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Inc., Teva, Mylan, Dr. Reddy's and Par Pharma
Jan 15, 2010
Uptrend Spotted in Shares of Dr Reddys Laboratories (RDY)
Jan 11, 2010
Dr. Reddy's to Release Q3 FY10 Results on Jan 20, 2010; Earnings Call Slated for Jan 20, 6.30 PM IST / 8.00 AM EST
Jan 11, 2010
SmarTrend research report available on Dr Reddys Laboratories (NYSE:RDY)
Jan 06, 2010
Health Stock Short-Squeeze Opportunities - TheStreet.com
Jan 06, 2010
More News
EARNINGS ESTIMATES
  This Quarter
03/2010
Next Quarter
06/2010
This Year
03/2010
Next Year
03/2011
Average Estimate 0.30 N/A 1.21 1.44
Number of Estimates 1 0 4 4
Low Estimates 0.30 N/A 0.93 1.14
High Estimate 0.30 N/A 1.62 1.70
Year Ago EPS 0.48 0.30 1.02 1.21
EPS Growth -37.50% N/A% 18.63% 19.21%

More Estimates

COMPANY DESCRIPTION
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection

Full Company Report
FINANCIALS
EPS TTM 1.37
Sales 1365
Net Income -208
Price/Earnings 17.04
Price/Book 4.17
Price/Cash Flow 15.84
Price/Sales 2.58


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research